Come join in meeting and discussing the latest topics on Aortic Diseases.
Come join in meeting and discussing the latest topics on Aortic Diseases.
It all started when I was watching TV. I bent over to look at my computer, and this pain felt like someone was taking a knife slicing me up the middle and up into my chest. At first, I thought that I may have strained a muscle because I was into working-out with weights but after a few minutes of this pain I knew something was terribly wrong.
I had this instinctive feeling that I couldn’t wait for a ambulance so I took myself to the hospital which was only a few miles away and I knew exactly where it was, because it was right next to my bank. When I got there they asked me all these questions about my pain, how severe it was and told them it was the worst pain that I ever felt, and if I felt nauseous.
After some tests, they told me that my aorta was splitting apart and I knew that having an aorta splitting apart is a serious situation. They gave me some morphine and prepared me to be transferred to another hospital which had a heart specialty facility. When I arrived at the hospital I was immediately put in cardiac Intensive care unit where I spent a few days talking to the nurses and family members.
After about the second day I fell into a coma and all I remember are these weird dreams . After 3 weeks I finally woke up by prodding by the nurses. Evidently, they wanted to come out of the coma, because what I heard was “Kurt time to get up” and them pulling at me to get me on my feet. They didn’t pull in a hard way, they were gentle with me.
I remember in my dreams was them making me stand up and sitting me in this chair. After six weeks I finally was released from Cardiac ICU and sent to physical rehabilitation for a week where I learned to walk and swallow again.
And finally released to my brothers care where nurse came for two weeks.
the effects were that my left hand is paralyzed, depression and sundry other problems and when I left rehabilitation they gave me about 15 prescriptions yo take for my blood pressure and various other problems.
Ok…. Here we go! Monday, I am scheduled to meet with Dr. James Brevig, it’s been over 15 years since my original ER surgery to save my life. I will be interested to hear what he has to say. I also have an echo of my aorta. I have never had this done and I think the reasoning was that I had a CT/Angio last year and they wanted to hold off on the radiation. I also am scheduled to see Gabe at the U of W later in December.
My main cardiologist, Dr. David Liang says that I don’t need surgery just quite yet and I trust him so very much!
More to come……..Brian 🙂
OK.. 12/3… I met with Dr. Brevig for almost an hour, he was great and said that he could do my surgery and I had a 5-6% risk factor. I would have my aortic root and valve replaced. The one really thing I like about Dr. Brevig, he’s calm and cool and very confident! The plan is surgery in Late June and an echo in May as well as a procedure to check my coronary arteries.
Yikes……………. I was at the ER last night for my wife. Just after my son has been complaining of chest pain, my wife woke up yesterday complaining of chest pain in the middle of her chest. So, off to the Providence Everett ER room. I have to say, they were great! She had a couple of EKG tests that did come back with a slight abnormality, as well as a d-dimer test and a few other blood tests plus a chest X-Ray.
We left after about 3 hours there and my wife is going to get stress test done early this week. She is still sleeping and I am hoping that her pain has gone away. However, I am concerned it could be something else like a clogged artery to the heart? Or high cholesterol, but hopefully the stress test and possible echo cardiogram will shed some light.
I have my first of 2 appointments with the doctor at Virginia Mason tomorrow about my value and aortic root issue as well as on 12/3 my appointment with Dr. James Brevig who did my original emergency open heart surgery at Providence Everett.
GOD…. Please help our family to get through this and have the hope to be strong in our faith.
My son was complaining about having a chest pains and he’d been off at college. He went to the WSU hospital and they said he had Mono. He wore a monitor for a few days and all tests came back clear. Then yesterday, he said he was still feeling pains and at dinner we ended up leaving and getting it to go.
Well, I took him to the ER at Providence Everett (where I had my surgery) and I told the ER doctor about my condition and that I wanted him to have a CT/Angio, D-dimer test and a partial echo. So, my wish was granted and he got all 3 and all the tests turned out clear. I was so scared that he might have some aortic condition or valve issue.
God IS GOOD! Jesus Christ is in charge!
Dr. Otto, my cardiologist the U of W.
I just have been doing more research and trying to find out where/when I would get my aortic valve, aortic root and possibly my aortic arch replaced. I think I have found, in fact, I know that I found the guy. Dr. Luis Castro The Sequoia Hospital Heart & Vascular Institute in Redding CA. It’s not in my state of Washington, but, this guys got the reviews and reputation as an expert w/proven results. Here’s a video he did. Here’s another one too! “Understanding Heart Valve Replacement Choices: What you need to know.”
I am going to see about sending my latest echo to him and getting his advice. As well as sending it to Dr. Liang at Stanford. However, Dr. Castro has my vote.
I am trying to figure out why I am feeling kind of nauseous lately. I started my BP meds (100mgs of Metroprolol and Mycardias/HCTZ 80/25) and I swear I felt light headed the day of my echo as my BP got up to 200/77. I don’t know if an aortic valve (leaky biscuspid) has this light headiness feeling.
I know the stress of making a decision affects all of my family and my wife being a school teacher, she will need some time off. But… I also don’t know how soon I will need the surgery either. I need to get a “firm” answer from Dr. Castro and take it from there.
Granted, it’s a bit old, still worth viewing.
Great success story!
I just found out this week that my aortic valve(bicuspid valve) is now leaking at the moderate/severe level and that my left ventricle is enlarged due to the overloading. Also, I was informed that my aortic root was at 5cm and my cardiologist, Dr. Otto at the University of Washington said it was time to start looking.
What was interesting is that they scheduled me to get another echo in 6 months, but said they would schedule me with the surgeon Dr. Ed Verrier.
So, I am waiting to see what that appointment will be. I also have another surgeon there Dr.Gabriel Aldea, that I want to see. As well as I have appointments with Dr. Paul Ryan at Swedish and also with my original surgeon Dr. James Brevig at Providence.
My decision to where to have my surgery is going to be based on who is the most qualified and which surgery institution has the best success rate. I am a bit leary of going to a teaching hospital such as the U of W, but my logic is simply I don’t want students assisting my surgery. I want the well run team that works well together. I am holding a bias only because I personally don’t know if my statement is actually true. My research has led me to wanting to do it at Swedish with Dr. Paul Ryan whom actually assisted Dr. James Brevig 15 years ago in Everett.
My existing Dacron tube will be removed and from what I gather, a longer piece will be required to cover the aortic root and in harmony, my leaking aortic valve replaced at the same time. Dr. Otto seems to think Ed Verrier is the most qualified. But, she’s biased for wanting her institution to do it. I am sure it would be a great learning experience as I doubt they have this many of my type of surgery requirements. I actually emailed Gabe at the U of W last night about my situation and will be interested to get his response. Gabe got back to me and he said both him and Ed could do the surgery.
I also reached out to Mr. Starnes at USC who is considered on of the top surgeons in the world regarding heart stuff. I hope to hear from him too.
God Bless, Jesus is coming soon!
Emergency doctors are being urged to collaborate with a patient-led campaign, which aims to reduce the number of patients dying in Irish Emergency Departments (EDs) from aortic dissection.
An aortic dissection refers to a tear in the body’s largest artery that carries blood away from the heart. Unless the condition is diagnosed rapidly and the patient undergoes surgery, it can prove fatal.
However, symptoms can be similar to other heart problems, such as a heart attack, which can lead to a misdiagnosis or a delay in diagnosis.
A patient support association, Aortic Dissection Awareness (UK and Ireland), is challenging the number of unnecessary deaths that occur due to the misdiagnosis of this condition in Irish hospitals.
It is calling on the Irish Association for Emergency Medicine (IAEM) to collaborate with it and introduce changes in relation to education, awareness and policy around the condition.
The chairperson, vice-chairperson and medical advisor of this patient association are attending the IAEM’s annual scientific meeting and conference in Dublin this week to urge doctors to get involved with the ‘Think Aorta’ campaign.
This campaign was inspired by the death of Tim Fleming, who was sent home from Dublin’s Tallaght Hospital in 2015 with an incorrect diagnosis of gastritis. Mr Fleming’s daughter, Catherine Fowler, who is vice-chairperson of Aortic Dissection Awareness, is a guest speaker at the conference.
“We had no idea when dad died of how common it is for aortic dissection to be missed in the ED. Over the last three years, the picture has become very clear. Sadly, I know of many other families in Ireland who have lost their relatives to missed aortic dissection in hospitals during that time. We must do something to change the future for others,” she said.
She pointed out that as a result of the ‘Think Aorta’ campaign in the UK, the Royal College of Emergency Medicine there has accepted that this is a real issue and it is working with the association to address this.
“I will be asking the IAEM to do the same,” Ms Fowler added.
Statistics show that aortic dissection is only considered in half of the patients who present with it, and one-third of patients are actively treated for something else, such as a heart attack.
The only definitive diagnostic tool for diagnosing the condition is a CT scan, however these are often not ordered until it is too late.
“Aortic dissection is not a difficult condition to diagnose. A doctor just has to be aware enough to ‘Think Aorta’ in the first place, then once their suspicion is raised, they must request an immediate CT scan to confirm.
“Experience in the UK shows that if EDs educate staff about aortic dissection and lower the barriers to CT scanning, lives will be saved,” Ms Fowler noted.
The IAEM annual scientific meeting and conference takes place in Castleknock Hotel from October 17-19. For more information on the ‘Think Aorta’ campaign, click here
MUNICH — Irbesartan in standard doses is linked to a significant decrease in the rate of aortic dilatation in patients with Marfan syndrome, according to data from the AIMS study presented at the European Society of Cardiology Congress.
In the AIMS trial, Michael Mullen, MBBS, MD, FRCP, from St. Bartholomew’s Hospital in London, and colleagues randomly assigned patients aged 6 to 40 years with Marfan syndrome at 22 centers in the United Kingdom to irbesartan or placebo. The researchers aimed to recruit 490 patients but only enrolled 192 patients.
After an initial run-in period during which all patients received irbesartan 75 mg, 104 patients were up-titrated to targets of 300 mg for patients weighing more than 50 kg and 150 mg for patients weighing less than 50 kg or placebo. Treatment with beta-blockers was not mandated but was encouraged because it is standard treatment, Mullen said.
Patients were followed for up to 5 years and underwent yearly echocardiograms, for which a core lab was used. The primary endpoint was annual change in aortic root diameter and secondary endpoints included annual change in z score and clinical events and requirement for surgery, including aortic dissection.
At baseline, there was a reasonable spread across various age groups, with approximately half of patients younger than 18 years and a good balance between male and female patients. Fifty-seven percent were also taking beta-blockers.
The overall study population was normotensive, and aortic root diameter was similar for the placebo (35.3 mm) and irbesartan groups (34.8 mm). The aortic z score was approximately 3 in both groups, “meaning that, compared with other trials, these patients were fairly early in pathogenesis of their disease,” Mullen said.
The rate of aortic dilatation was slower in patients taking irbesartan vs. placebo, with a mean annual rate of change in aortic root diameter of 0.53 mm in the treatment group vs. 0.74 mm in the placebo group (difference, –0.22 mm; 95% CI, –0.41 to –0.02). Significant differences in the change in aortic root diameter were apparent at 1 year and continued out to 5 years, according to Mullen.
In terms of safety, irbesartan was well-tolerated, with four patients in both the placebo and irbesartan groups failing to tolerate medication. There was also no difference in the rate of adverse events between groups. Four patients in both groups underwent cardiac surgery, but the study was again not powered to detect differences in clinical outcomes, according to Mullen. No deaths occurred during the study.
Aortic z score, which adjusted the aortic diameter for patients’ body surface area and particularly any changes in body surface area, appeared to be fairly stable in the irbesartan group (annual rate of change, 0.05; 95% CI, –0.2 to 0.11) when compared with the placebo group (annual rate of change, 0.15; 95% CI, 0.08-0.22). The difference of –0.1 (95% CI, –0.19 to –0.01) was statistically significant, Mullen noted.
The researchers also evaluated the effect of treatment on BP, as irbesartan is a well-recognized antihypertensive treatment, he said. Results showed a significant reduction in systolic BP in patients taking irbesartan vs. placebo (–0.42 mm Hg vs. 1.27; mean difference, –1.69 mm Hg), which was maintained out to 5 years.
There was no difference in treatment effect of irbesartan in patients taking beta-blockers vs. those who were not, suggesting that there was no interaction or synergy between the two drugs. The annual rate of change in aortic diameter between study groups was also not significantly different when analyzed according to aortic z score. Additionally, no statistically significant difference was noted based on patient age, although the effect size appeared to be numerically larger in younger patients.
However, Mullen noted that the study was significantly underpowered to analyze subgroups and suggested interpreting the results with caution.
The results of this study, according to Mullen, suggest that irbesartan may have potential benefits for patients with Marfan syndrome.
“The current treatment strategy is based around beta-blockade, based on small trials conducted many years ago, and monitoring aortic dimensions with timely surgical intervention. However, some patients will still experience aortic dissection prior to presentation or before reaching those thresholds for surgical intervention,” Mullen said. “If translated into clinical practice, long-term irbesartan treatment may impact favorably on clinical outcomes in patients with Marfan syndrome.”
During a discussion of the results, Artur Evangelista Masip, MD, PhD, from Hospital Universitari Vall d’Hebron in Barcelona, Spain, highlighted several issues that may affect these findings, including the study’s sample size.
Evangelista Masip also noted that the inclusion of children and adults in the same series complicates the ability to perform an accurate analysis of this study as well as other trials. The measurement of changes in aortic diameter in systole may also be affected by the reduction in systolic BP.
“It would be interesting to know their results measuring at end-diastole,” he said.
Additionally, Evangelista Masip said the difference in the rate of change in aortic root diameter between the irbesartan and placebo groups occurred mainly during the first year and was similar thereafter.
“This is an important study and I agree that long-term irbesartan treatment may impact favorably in the evolution of patients with Marfan syndrome,” he said. “However, we have to clarify some of the previous doubts and elucidate in future studies if the reduction or aortic enlargement is secondary to biological effect or related to the decrease of BP.” – by Melissa Foster
Mullen M. Hot Line Session 5. Presented at: European Society of Cardiology Congress; Aug. 25-29, 2018; Munich.
Disclosures: Mullen and Evangelista Masip report no relevant financial disclosures.
ORONO, Maine — Orange County High School football standout Darius Minor died July 24 after he collapsed during a preseason football workout at the University of Maine, according to a university spokesperson. Minor, 18, was a first-year student at the university and was set to play defensive back on the school’s football team.
“The Athletics Department, our student-athletes and the entire campus mourn the loss of this bright and promising member of our community,” UMaine President Joan Ferrini-Mundy said. “We ask all to keep him, his family and his friends in your thoughts.”
Minor collapsed on the football field during a “supervised light workout” Tuesday at about 1:15 p.m., according to the university. The team’s training staff and first responders were not able to resuscitate him.
“Words cannot express the grief we have following this tragic loss,” UMaine head coach Joe Harasymiak said. “Our thoughts and prayers go out to Darius’ family and friends during this terrible time.”
In high school, Minor led his Orange County High School to three-consecutive post season appearances. He was named All-Central Virginia first-team wide receiver and second-team defensive back in 2017.
The Locust Grove teen was to be a political science major at the University of Maine.
Exposure to fluoroquinolones—one of the most popular classes of antibiotics in the world—is associated with more than double the risk of aortic aneurysm (AA) or aortic dissection (AD), according to a study published online in the Journal of the American College of Cardiology.
Using national databases from Taiwan, researchers analyzed fluoroquinolone prescriptions among 1,213 patients hospitalized for AA or AD from 2001 to 2011. They compared exposure to the drug in the 60 days leading up to the AA/AD event to a randomly selected 60-day interval between 60 and 180 days before the event.
Lead author Chien-Chang Lee, MD, ScD, and colleagues found 1.6 percent of patients had been exposed to fluoroquinolone in the two months leading up to their event, versus only 0.6 percent in a preceding 60-day period. That translated to a 2.71-fold risk of AA/AD related to more recent fluoroquinolone use.
In addition, Lee et al. found that prolonged exposure to the antibiotics further increased risk. Those who were prescribed the drugs for between three and 14 days showed a 2.41-fold increased risk versus no prescription at all, while those prescribed fluoroquinolones for more than 14 days demonstrated a 2.83-fold risk.
“Typically, AA/AD develop slowly in patients, but our data suggest that use of fluoroquinolone can contribute in the short term to aneurysm progression or rupture that may require emergency department visits and hospitalization,” wrote Lee, with the department of emergency medicine at National Taiwan University Hospital, and coauthors.
Population-based studies support that AA and AD are rare diseases, occurring in between three and 20 people per 100,000 population each year. However, annual incidence among elderly individuals rises to as much as 130 per 100,000 people, the researchers noted.
Despite the relative rarity of the conditions, Lee et al. suggested the rising prescriptions of fluoroquinolones may be cause for concern, particularly since AA and especially AD are life-threatening without timely treatment.
The authors estimated 25.2 million U.S. outpatients were prescribed fluoroquinolones in 2012, which they calculated would result in an additional 2,591 cases of AA/AD.
“In the United States alone, fluoroquinolone prescriptions have more than tripled, from 7 million in 1995 to 22 million in 2002. With an estimated 25 million people prescribed with fluoroquinolones in the United States annually, which is expected to increase even more, it is clear that fluoroquinolones may contribute substantially to the current and future burdens of AA/AD.”
In a related editorial, Sonal Singh, MD, MPH, and Amit Nautiyal, MD, noted fluoroquinolones “have been known to cause tendon rupture mediated by their adverse effects on collagenous structures”—and the aorta is rich in type I and type III collagen.
“Although the exact biological mechanism remains unknown, several plausible mechanisms have been proposed to explain how fluoroquinolones might affect the synthesis or structural integrity of collagen in the aortic wall,” Lee and colleagues wrote. “First, fluoroquinolones have chelating properties against several metal ions (e.g., calcium, magnesium, aluminum), which are essential for type 1 collagen synthesis. Second, fluoroquinolones can decrease collagen synthesis by increasing the expression of matrix metalloproteinases, which lead to extracellular matrix degradation and medial layer degeneration.”
Based on the biological plausibility of those experimental studies—as well as the consistently increased risk found in epidemiological research—Lee et al. believe there is strong evidence to support that fluoroquinolone contributes to the incidence of AA and AD.
“Although the rare incidence of AA/AD attenuates the public health impact, the rapid increase of fluoroquinolone consumption still poses a large burden of AA/AD in the general population,” they wrote. “Clinicians are advised to consider alternative antibiotic regimens in patients with pre-existing collagen-related disorder or aortic aneurysm.”
Singh and Nautiyal agreed, saying the “cumulative strength” of multiple studies, with different designs and different patient populations, makes it unlikely an unknown confounding factor is biasing all of the studies.
“It would be prudent to entertain the possibly of aortic aneurysms/aortic dissection associated with fluoroquinolones use in patients presenting with chest pain, shortness of breath, or syncope after recent exposure to the fluoroquinolones,” they wrote. “Although one should be careful in extrapolating from mechanistic studies, judicious use of fluoroquinolones may be particularly warranted among patients with risk factors for aortic aneurysms such as increasing age, the presence of smoking, hypertension, and Marfan’s syndrome.”
Hope this finds you well, I am working on the grant application for PCORI as I mentioned to you earlier. So more information will be coming in the next week.
“Also, I recently published these manuscripts recently that you may find to be of interest to your readership’
Association of variant arch anatomy with type B aortic dissection and hemodynamic mechanisms
· Type of Research: Retrospective cohort study
· Take Home Message: Compared with 367 controls, variant arch anatomy was observed on computed tomography scans of 40.5% of 185 patients with type B aortic dissection. On four-dimensional flow magnetic resonance imaging, patients with bovine arch had higher systolic wall shear stress compared with those with normal arch anatomy.
· Recommendation: This study suggests that aortic arch anatomy variants are more common in patients with type B aortic dissections, which might be explained by higher wall sheer shear stress.
Endovascular thoracic aortic repair in confirmed or suspected genetically triggered thoracic aortic dissection
· Type of Research: Retrospective analysis of prospectively collected National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions (GenTAC) data
· Take Home Message: In 31 patients with descending thoracic aorta dissection treated with thoracic endovascular aortic repair, 13 (42%) required reintervention at a median of 7 months, 3 for retrograde ascending aorta dissection and 7 for thoracoabdominal aortic aneurysm repairs with stent graft explantation.
· Recommendation: This study suggests that patients with genetically triggered descending thoracic aorta dissection, treated with thoracic endovascular aortic repair, have a high risk of retrograde aortic dissection and reintervention.
Testing patterns for genetically triggered aortic and arterial aneurysms and dissections at an academic center
· Type of Research: Retrospective cohort study
· Take Home Message: In 36% of 75 patients suspected of having heritable mutations related to aortic or arterial aneurysms or dissections, genetic testing results were positive. Pathogenic mutation was confirmed in 57% of patients with a family history of diagnosed mutation and in 42% of those with a personal history of ascending aortic disease.
· Recommendation: The authors suggest appropriate genetic consultation and selective testing in patients suspected of having genetically triggered vascular disease and suggest the need for novel gene discovery.
Sherene Shalhub, MD MPH FACS
Associate Professor of Surgery
Division of Vascular Surgery
University of Washington
There was a low growth rate for moderately dilated ascending aorta, according to a systematic review and meta-analysis published in JAMA Network Open.
Ming Hao Guo, MD, of the division of cardiac surgery at University of Ottawa Heart Institute, Canada, and colleagues analyzed data from 8,800 patients (mean age, 58 years; 76% men) from 20 studies from 1946 to May 2017. Studies were included in the meta-analysis if they reported rate of dissection or rupture, growth rate or all-cause mortality in patients with ascending aortic aneurysm.
Intensified therapy improves outcomes for childhood B-cell acute lymphoblastic leukemia subgroup
Risk for cancer-associated thrombosis high with implanted ports
Increased endometrial cancer incidence prompts calls for more screening, research funding
Data that were extracted include study design, demographics, follow-up, sample size, initial aneurysm diameter, patient risk factors and comorbidities, incidence of dissection or rupture, aneurysm growth rate during follow-up, incidence of elective ascending aortic surgery, size at dissection or rupture and all-cause mortality. Total follow-up time was 31,823 patient-years.
At enrollment, the mean initial aneurysm size from 13 studies was 42.6 mm.
All studies had a combined effect estimate for annual growth rate of 0.61 mm per year (95% CI, 0.23-0.99; I2 = 92%). During a median follow-up of 4.2 years, the pooled incidence of elective aortic surgery was 13.82% (95% CI, 6.45-21.41; I2 = 56%).
The linearized rate of the composite outcome of aortic dissection, all-cause mortality and aortic rupture was 2.16% per patient-year (95% CI, 0.79-3.55, I2 = 64%). The linearized rate for all-cause mortality was 1.99% per patient-year (95% CI, 0.83-3.15; I2 = 84%).
Researchers did not find a significant relationship between the year of study completion and primary outcomes and initial aneurysm size.
“These results require cautious interpretation as a large number of patients in the studies who met guideline criteria for intervention underwent elective aortic surgery,” Guo and colleagues wrote. “More robust natural history data from prospective studies or randomized clinical trials are necessary to better inform clinical decision-making in patients with ascending aortic disease.”
In a related editorial, Thoralf M. Sundt, MD, chief of the division of cardiac surgery and director of the Corrigan Minehan Heart Center at Massachusetts General Hospital, wrote: “To be sure, for patients, once they have been told they have an aneurysm (read, ‘time bomb in your chest’), it is very hard to turn back the clock and reassure them that the likelihood of a catastrophe is low. I suspect the same is true, to some degree, among caregivers. Who among us wants to sit by watching and hoping that we do not get a phone call that an aorta has dissected? Furthermore, our outcome information is asymmetric. The absence of dissection is a nonevent; we do not see it because there is nothing to see. And, of course, we can never know how many of those aortas we replace would or would not have dissected.” – by Darlene Dobkowski
Disclosures: The authors and Sundt report no relevant financial disclosures.
Laurie Gonzales-Lewis of Idaho Falls nearly died during surgery to repair an aortic aneurism. | Courtesy photo
IDAHO FALLS – Members of the community are coming together to help an Idaho Falls woman.
Laurie Gonzales-Lewis recently suffered an aortic aneurism. Brittni Messenger, Lewis’ daugher, tells EastIdahoNews.com the aorta began to expand like a balloon. Fluid began leaking in to Lewis’ heart and started crushing it.
When doctors began surgery to repair the problem, they discovered Lewis had an aortic dissection, which was causing her aorta to unravel from the inside out.
“It was shooting blood clots straight up her brain and down to her leg,” Messenger says.
Gonzales-Lewis’ heart stopped twice during this procedure. She spent the next ten days in sedation. Messenger says her mom was declared brain dead and only given a 15-percent chance of survival.
Then, just two days later, Gonzales-Lewis woke up. For three days, everything seemed normal until doctors noticed something unusual.
“The clots were killing all the tissue. It was causing her excruciating pain until blood flow in the the top half of her right foot stopped,” Messenger says.
Doctors amputated her right leg from the knee down.
Gonzales-Lewis’ condition now requires constant care. Messenger says her step-dad is so busy taking care of her mom that he is unable to work. Disability and insurance benefits don’t kick in until October, leaving them with no means of financial support.
Now Messenger and others are hosting a fundraiser to help with medical costs and a prosthetic leg for Lewis.
The fundraiser kicks off at 5 p.m. Saturday inside York Hall at 954 W. 65th S. Dinner will be served, followed by a raffle around 6:30 p.m.
The cost is $18 for adults, $8 for kids six and up. Kids five and under are free. Each purchase comes with a $5 raffle ticket.
“Anything (people can contribute) is so appreciated right now. It’s been such a hard time for her. It’s completely changed her lifestyle and she’s had to readapt to everything. But it’s amazing that she’s here and we are grateful for the community support,” says Messenger.
York Hall is located in the vicinity of the Budweiser plant.
To learn more about the Benefit dinner and raffle, visit their Facebook page.